Novartis, Kisqali and breast cancer
Novartis CEO says FDA's extended approval of breast cancer drug is a 'landmark' for the firm
Vas Narasimhan, CEO of Novartis, comments on the progress of the firm's Kisqali metastatic breast cancer drug after the company recently received an extended approval for it from the U.S. Food and Drug Administration.
FDA expands Novartis’ Kisqali label to include early breast cancer patients
Kisqali generated $2bn in sales last year, with broader approvals forecasting sales of over $8bn by 2030, per GlobalData analysis.
Novartis: Kisqali Reduces Recurrence Risk By 28.5% In Late-stage Early Breast Cancer Trial
Novartis Pharma AG, affiliated to Swiss drug major Novartis AG (NVS), announced Monday updated analysis from the pivotal Phase III
USFDA approves Novartis' Kisqali for early-stage breast cancer treatment
This approval marks a breakthrough for individuals diagnosed with hormone receptor-positive (HR+)/HER2-negative stage II and III early breast cancer, including those without lymph node involvement.
Novartis' Kisqali Lowers Risk of Breast Cancer Recurrence by 28%
NVS' breast cancer drug Kisqali reduces the risk of disease recurrence by 28.5% in a broad population of patients suffering from early breast cancer.
Novartis’ breast cancer trial of Kisqali reveals 28.5% risk reduction
Kisqali is a selective cyclin-dependent kinase inhibitor that targets proteins involved in the rapid division of cancer cells.
Novartis Breast Cancer Drug Found To Cut Disease Recurrence
American depositary receipts (ADRs) of Novartis (NVS) gained Monday as new research showed the company's breast cancer treatment, Kisqali, produced longer success than originally thought.The company reported an updated analysis of a Phase 3 clinical trial of Kisqali combined with endocrine therapy (ET) found "a deepening benefit beyond the three-year treatment period,
Novartis' Multiple Sclerosis Drug Data Shows Most Patients Remain With No Disability Progression For Up To Six Years
Novartis AG (NYSE:NVS) released new data Wednesday from the ALITHIOS open-label extension study. Data show first-line ...
Novartis4d
New Novartis data in relapsing MS reinforce benefits of Kesimpta® for first-line and switch patients
A separate US-based single-arm OLIKOS Phase IIIb study showed that at 12 months, all clinically stable RMS patients who switched from intravenous (IV) anti-CD20 therapy to Kesimpta showed no new ...
STAT4d
FDA awards Novartis expanded approval for breast cancer therapy
The potential market for the Novartis drug Kisqali could grow markedly, now that certain early-stage breast cancer patients ...
How Novartis plans to thrive without competing directly with Eli Lilly in weight loss drug market
Novartis says it's not interested in joining weight-loss drugs frenzy. CEO Vas Narasimhan explained why today on CNBC's "Squawk Box Europe".
GE Healthcare wins FDA clearance for Alzheimer’s imaging software
The clearance adds a Centiloid scale tool to GE Healthcare’s Mim software to help clinicians determine the density of amyloid ...
Novartis lower as BofA downgrades on risks to valuation
Novartis (NVS) stock traded lower after Bank of America downgraded the Swiss drugmaker to neutral, citing a cautious outlook ...
The Lancet2d
Sexual health and emotional wellbeing of adolescent and young adult survivors of haematological malignancies
This Comment is linked to The Lancet Haematology Series on Sexual Health in Patients with Haematological Malignancies; we ...